Moderna Stock News

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.

NEW YORK , Sept. 23, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292...

Pfizer and Moderna have seen their shares drop as their coronavirus-related tailwind ended. Yet, both companies have exciting pipelines and have earned important approvals recently.

NEW YORK , Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA).

Moderna is terminating a handful of pipeline programs and looking to cut costs. It's also trying to launch a slew of programs over the next few years.

Moderna's stock has fallen due to the weak management revenue guidance, but I remain positive about its long-term potential. Key developments include the next-gen COVID-19 vaccine, the RSV vaccine, and promising pipeline drugs like the cytomegalovirus and cancer vaccines. Management's 2024 revenue guidance is conservative. I expect Moderna to outperform it.

If you're like many investors, you may feel this isn't your normal bull market. For every data point supporting a strengthening economy, you can find one or more that suggest things are weaker than expected.